PMID- 15140128
OWN - NLM
STAT- MEDLINE
DCOM- 20050114
LR  - 20230829
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 2
IP  - 6
DP  - 2004 Jun
TI  - Activity of a synthetic hexadecasaccharide (SanOrg123781A) in a pig model of 
      arterial thrombosis.
PG  - 925-30
AB  - The activity of SanOrg123781A, a new synthetic antithrombotic drug inhibiting 
      both factor Xa and thrombin through antithrombin (AT), was compared to that of 
      unfractionated heparin (UFH) and of the synthetic pentasaccharide (fondaparinux, 
      SP) in an ex vivo arterial thrombosis model in the pig. Six groups of four pigs 
      were administered intravenously with SanOrg123781A (1, 3, 10 and 30 nmol kg(-1)), 
      UFH (30 nmol kg(-1)) or SP (30 nmol kg(-1)). In this arterial model in which 
      platelet thrombus was formed on a thrombogenic surface under a constant high 
      shear rate, UFH and SP had moderate antithrombotic effects while SanOrg123781A 
      exhibited a strong, dose-dependent inhibitory activity on platelet adhesion and 
      platelet thrombus formation. In contrast to UFH, SanOrg123781A did not modify the 
      activated partial thromboplastin time (aPTT) even at 30 nmol kg(-1), but strongly 
      inhibited thrombin generation. At the same dose, despite a lower antithrombotic 
      activity than SanOrg123781A, UFH significantly affected all the coagulation 
      parameters. Taken together, these results show that SanOrg123781A, due to its 
      potent and selective antifactor Xa and antifactor IIa activities is a promising 
      new antithrombotic agent even in arterial setting.
FAU - Bal dit Sollier, C
AU  - Bal dit Sollier C
AD  - Laboratoire de Thrombose et d'Atherosclerose, IVS-INSERM Hopital Lariboisiere, 
      Paris and INRA, Jouy en Josas, France. claire.bal@lrb.ap-hop-paris.fr
FAU - Kang, C
AU  - Kang C
FAU - Berge, N
AU  - Berge N
FAU - Herault, J P
AU  - Herault JP
FAU - Bonneau, M
AU  - Bonneau M
FAU - Herbert, J M
AU  - Herbert JM
FAU - Drouet, L
AU  - Drouet L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Polysaccharides)
RN  - 0 (SanOrg 123781)
RN  - 9001-26-7 (Prothrombin)
RN  - 9002-04-4 (Factor IIa)
RN  - 9005-49-6 (Heparin)
RN  - J177FOW5JL (Fondaparinux)
SB  - IM
MH  - Animals
MH  - Blood Platelets/drug effects
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation, Preclinical
MH  - Factor Xa Inhibitors
MH  - Fondaparinux
MH  - Heparin/administration & dosage/pharmacokinetics/pharmacology
MH  - Partial Thromboplastin Time
MH  - Polysaccharides/administration & dosage/*pharmacokinetics/pharmacology
MH  - Prothrombin/antagonists & inhibitors
MH  - Swine
MH  - Thrombosis/*drug therapy/prevention & control
EDAT- 2004/05/14 05:00
MHDA- 2005/01/15 09:00
CRDT- 2004/05/14 05:00
PHST- 2004/05/14 05:00 [pubmed]
PHST- 2005/01/15 09:00 [medline]
PHST- 2004/05/14 05:00 [entrez]
AID - S1538-7836(22)15797-1 [pii]
AID - 10.1111/j.1538-7836.2004.00719.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2004 Jun;2(6):925-30. doi: 10.1111/j.1538-7836.2004.00719.x.